Article
Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.
Hepatology (Baltimore, Md.) - 1 Nov 2013
Pedersen Jannie, Carlsen Thomas H R, Prentoe Jannick, Ramirez Santseharay, Jensen Tanja B, Forns Xavier, Alter Harvey, Foung Steven K H, Law Mansun, Gottwein Judith, Weis Nina, Bukh Jens
Abstract excerpt
UNLABELLED: Immunotherapy and vaccine development for hepatitis C virus (HCV) will depend on broadly reactive neutralizing antibodies (NAbs). However, studies in infectious strain JFH1-based culture systems expressing patient-derived Core-NS2 proteins have suggested neutralization resistance for specific HCV strains, in particular, of genotype 2. To further examine this phenomenon, we developed a panel of HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
